Influenza is typically a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated with influenza illness. Annual vaccination should be offered to all persons ≥6 months old as long as influenza viruses are circulating in the community.1
TREATMENT OF INFLUENZA — Antiviral treatment is recommended as...
ISSUE
Tavapadon (Juvmo – Abbvie), an oral nonergot partial dopamine agonist, has been approved by the FDA for treatment of Parkinson's disease (PD).
STANDARD TREATMENT — The combination of levodopa and carbidopa is the most effective treatment for the motor symptoms of PD.1 For the first 2-5 years of treatment, it produces a consistent response, but as the disease progresses, the duration of benefit from each dose becomes shorter (wearing-off effect) and patients experience fluctuations between mobility and immobility (on-off effect). After 5-8 years, most patients experience worsening of motor fluctuations and dyskinesia.
Nonergot dopamine agonists (see Table 2) are less likely to cause motor fluctuations and dyskinesia than carbidopa/levodopa. They are effective as monotherapy in early, mild PD, but most patients require addition of carbidopa/levodopa within a few years. Used as …